| palbociclib based treatment |
| palbociclib plus fulvestrant |
| la/mBC - HR-positive - 2nd line (L2) 20 | |
| la/mBC - HR positive - L2 - all population 1 | |
| la/mBC - HR positive - L2 - PIK3CA mutant 1 | |
Comparator:
vs fulvestrant;
Risk of bias:
low;
some concerns;
high;
NA;